COMMUNIQUÉS West-GlobeNewswire

NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
08/05/2025
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across [...]
EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education
08/05/2025
ZURICH, May 08, 2025 (GLOBE NEWSWIRE) -- The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong [...]
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA
08/05/2025
Milan, ITALY – 8 May 2025 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces an upcoming oral presentation showcasing [...]
Pharming Group reports first quarter 2025 financial results and provides business update
08/05/2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued [...]
Zealand Pharma Announces Financial Results for the First Three Months of 2025
08/05/2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and [...]
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC [...]
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update
08/05/2025
Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results [...]
Interim report Q1 2025
08/05/2025
Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “ We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. [...]
Swarm Oncology to present at Bio€quity Europe 2025
08/05/2025
London, U.K., May 8 2025 , Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today [...]
Emergent BioSolutions Reports First Quarter 2025 Financial Results
07/05/2025
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and [...]
electroCore Announces First Quarter 2025 Financial Results
07/05/2025
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170, [...]
InnovAge Earns Recertification as a Great Place to Work
07/05/2025
Employee feedback highlights pride in and commitment to serving the community DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- InnovAge, a leading provider of Program of All-Inclusive Care for the Elderly (PACE) services, is [...]
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
Interim Data from Low Dose Cohort in MyPEAK TM -1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History [...]
Exagen Inc. Announces Proposed Public Offering of Common Stock
07/05/2025
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its [...]
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
07/05/2025
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and [...]
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
07/05/2025
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million — Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, [...]
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
07/05/2025
First Quarter 2025 Revenue Increased 17% Year-over-Year WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]
OraSure Announces First Quarter 2025 Financial Results
07/05/2025
BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
07/05/2025
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Pages